Requires certain health insurance to cover certain screenings for certain genetic disorders. (BDR 57-1104)
SB344 requires a broad set of Nevada health insurers and health coverage programs to cover noninvasive prenatal screening during pregnancy. The bill applies to group health insurance policies, health benefit plans, benefit contracts, hospital and medical services corporations, health maintenance organizations, managed care organizations, fraternal benefit societies, and Medicaid, and it defines the covered service as a blood draw and laboratory analysis of fetal DNA in maternal blood to detect chromosomal abnormalities in the fetus. Coverage must be provided without prior authorization, and policies or contracts issued, delivered, or renewed on or after January 1, 2026, are deemed to include the required benefit regardless of conflicting plan language.
The bill also amends Nevada insurance and Medicaid-related statutes to make these coverage requirements enforceable across multiple regulatory frameworks. It authorizes the Insurance Commissioner to suspend or revoke the certificate of authority of a health maintenance organization that fails to comply with the new requirements, and it directs the Department of Health and Human Services to administer the Medicaid provision and seek any necessary federal waiver or state plan amendment. SB344 includes a General Fund appropriation to the Division of Health Care Financing and Policy to cover Medicaid implementation costs for fiscal years 2025-2026 and 2026-2027.
The overall sentiment reflected in the bill’s legislative history is strongly supportive. The bill passed the Senate unanimously, 20-0, and the Assembly unanimously, 40-0, indicating broad bipartisan agreement on expanding access to prenatal genetic screening. No committee transcript excerpts were provided, but the unanimous votes suggest little recorded opposition in the formal voting history.
The main policy issue underlying the bill is access versus cost and administrative burden. Supporters appear to favor earlier and broader access to prenatal screening, especially by eliminating prior authorization and extending coverage to Medicaid and managed care plans. Potential points of contention, though not reflected in the votes, would likely involve the added premium or public program costs, the need for state appropriations, and the requirement that Medicaid seek federal approval before the benefit can be fully implemented.
SB344 expands Nevada insurance mandates by adding noninvasive prenatal screening to the list of required covered benefits across multiple private and public health coverage categories. It amends numerous chapters of NRS governing group insurance, health benefit plans, fraternal benefit societies, hospital and medical services corporations, HMOs, Medicaid managed care, and state employee/local government coverage, while also prohibiting prior authorization for the screening. The bill further gives the Insurance Commissioner enforcement authority over noncompliant HMOs and appropriates state funds to support Medicaid implementation.
The bill appears to have enjoyed very strong support. It passed both chambers unanimously, with no recorded dissent in the final votes, suggesting broad agreement that the screening should be covered and that prior authorization should not be required. The absence of committee transcript material limits more detailed insight, but the voting history indicates a favorable and noncontroversial reception overall.
No formal opposition is shown in the available record, but the likely areas of concern are implementation cost, insurance premium impact, and Medicaid financing. The bill requires a state appropriation and depends on federal financial participation for Medicaid coverage, so fiscal and federal-approval issues are the main practical constraints. Another possible point of contention is the removal of prior authorization, which limits insurer utilization controls, though the unanimous votes suggest these concerns did not generate significant legislative resistance.